Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

Published

Journal Article

Aberrant signaling pathways are a hallmark of cancer. A variety of strategies for inhibiting signaling pathways have been developed, but monoclonal antibodies against receptor tyrosine kinases have been among the most successful. A challenge for these therapies is therapeutic unresponsiveness and acquired resistance due to mutations in the receptors, upregulation of alternate growth and survival pathways, or inadequate function of the monoclonal antibodies. Vaccines are able to induce polyclonal responses that can have a multitude of affects against the target molecule. We began to explore therapeutic vaccine development to antigens associated with these signaling pathways. We provide an illustrative example in developing therapeutic cancer vaccines inducing polyclonal adaptive immune responses targeting the ErbB family member HER2. Further, we will discuss new strategies to augment the clinical efficacy of cancer vaccines by enhancing vaccine immunogenicity and reversing the immunosuppressive tumor microenvironment.

Full Text

Duke Authors

Cited Authors

  • Clay, TM; Osada, T; Hartman, ZC; Hobeika, A; Devi, G; Morse, MA; Lyerly, HK

Published Date

  • April 2011

Published In

Volume / Issue

  • 49 / 1-3

Start / End Page

  • 235 - 247

PubMed ID

  • 21136201

Pubmed Central ID

  • 21136201

Electronic International Standard Serial Number (EISSN)

  • 1559-0755

International Standard Serial Number (ISSN)

  • 0257-277X

Digital Object Identifier (DOI)

  • 10.1007/s12026-010-8186-6

Language

  • eng